<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/82321AD2-CD2E-456C-9395-59CF155A3EC8"><gtr:id>82321AD2-CD2E-456C-9395-59CF155A3EC8</gtr:id><gtr:name>Sanofi</gtr:name><gtr:address><gtr:line1>174 avenue de France</gtr:line1><gtr:line4>Paris cedex 13</gtr:line4><gtr:postCode>75635</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>France</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4B8017E5-40E0-4ED8-9216-7010746F9003"><gtr:id>4B8017E5-40E0-4ED8-9216-7010746F9003</gtr:id><gtr:name>Institute of Cancer Research UK</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C80FA399-9F25-4473-8481-C60F0F3D5D18"><gtr:id>C80FA399-9F25-4473-8481-C60F0F3D5D18</gtr:id><gtr:name>Cancer Research UK Cambridge Institute</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:department>Unlisted</gtr:department><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/82321AD2-CD2E-456C-9395-59CF155A3EC8"><gtr:id>82321AD2-CD2E-456C-9395-59CF155A3EC8</gtr:id><gtr:name>Sanofi</gtr:name><gtr:address><gtr:line1>174 avenue de France</gtr:line1><gtr:line4>Paris cedex 13</gtr:line4><gtr:postCode>75635</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>France</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4B8017E5-40E0-4ED8-9216-7010746F9003"><gtr:id>4B8017E5-40E0-4ED8-9216-7010746F9003</gtr:id><gtr:name>Institute of Cancer Research UK</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C80FA399-9F25-4473-8481-C60F0F3D5D18"><gtr:id>C80FA399-9F25-4473-8481-C60F0F3D5D18</gtr:id><gtr:name>Cancer Research UK Cambridge Institute</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/90051600-6EF2-4093-BA8C-2B4B6F550895"><gtr:id>90051600-6EF2-4093-BA8C-2B4B6F550895</gtr:id><gtr:name>University of Dundee</gtr:name><gtr:address><gtr:line1>University of Dundee</gtr:line1><gtr:line2>Nethergate</gtr:line2><gtr:postCode>DD1 4HN</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/CE111F08-A99D-413C-A205-1AEAF8376B5B"><gtr:id>CE111F08-A99D-413C-A205-1AEAF8376B5B</gtr:id><gtr:firstName>Colin</gtr:firstName><gtr:surname>Watts</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G108%2F507"><gtr:id>865C95F6-7672-46E6-96EB-2E338F6ED7B0</gtr:id><gtr:title>A systematic investigation of the effect of neural injury on the survival, development and migration of adult neural ste</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G108/507</gtr:grantReference><gtr:abstractText>Our scientific and clinical attitudes to injury of the brain and spinal cord are changing. Human neural stem cells offer the potential for developing new therapies to replace lost cells and deliver biologically active substances, such as growth factors, to the central nervous system. Recent investigations have demonstrated that neural stem cells are not confined to embryos but are also present in the adult brain including man. These cells may have a limited capacity to replace lost cells in a process of self-repair. Unfortunately this response is normally overwhelmed by the inflammation and scarring associated with disease. 

In order to utilise stem cells we need to (1) learn how to turn them into the cells we want to replace (e.g. dopamine cells in Parkinson?s disease) and (2) help the cells get to the site of injury and circumvent any glial scarring process. 

The four investigations proposed in this project aim to begin to address this second problem by characterising the effect of injury and scarring on a) stem cells already present in the mature adult brain and b) on implanted stem cells. 

The project then goes on to begin to look at how we can obtain adult human neural stem cells and how they behave in response to injury. The results will increase our understanding of how stem cells respond to neural injury and how they might be manipulated to develop novel therapies to treat disease. This in turn would make the use of human embryonic tissue unnecessary and by using the bodies own cells avoid the need for immunosuppressive drugs.</gtr:abstractText><gtr:technicalSummary>Objective: To characterise the effect of neural injury on adult stem cell behaviour and hence determine how adult stem cells may be incorporated into strategies to repair the damaged central nervous system.

An integrated series of 4 studies are proposed. The first will characterise the effect of excitotoxic and mechanical damage on the ability of endogenous adult neural progenitors to continue to proliferate and to be recruited into areas of neural injury. This in vivo study will use cell migration in the rostral migratory stream as a model system based upon previous studies in intact animals. Cells will be labelled with a reporter gene and their fate and distribution investigated over time. This will form the basis for the second study.

The second study will investigate the effect of neural injury on the survival and behaviour of implants of adult neural stem cells. Tissue will be expanded in vitro and labelled to enable the fate and distribution of the cells to be determined. The ability of stem cells to re-populate areas of neural damage will also be studied.

The third study involves a different experimental paradigm, which seeks to evaluate the interaction between reactive astrocytes and migrating progenitors in vitro. The effect of manipulation of cell adhesion molecules in the extracellular matrix on progenitor cell migration over astrocytes will be investigated. This will lead to studies in vivo to determine how stem cells react interact with areas of reactive astrocytes at different stages of maturity.

The final study will begin to characterise the behaviour of human adult neural stem cells derived from clinical material obtained during routine neurosurgical practice. Techniques for harvesting and expanding human adult progenitors in vitro will be developed based on reported data. The study then aims to go on to investigate their behaviour in vivo.</gtr:technicalSummary><gtr:fund><gtr:end>2008-12-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2003-03-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>770608</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sanofi</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Genzyme Corporation</gtr:department><gtr:description>Genzyme Phage Project</gtr:description><gtr:id>4CF2A968-5BB3-4D72-A418-2A3FE3C426F8</gtr:id><gtr:impact>Data on novel epitopes held by genzyme. This has not been published or disclosed</gtr:impact><gtr:outcomeId>eppYmbH4sy2-1</gtr:outcomeId><gtr:partnerContribution>Phage analysis &amp;amp; validation of novel epitopes</gtr:partnerContribution><gtr:piContribution>Generation of patient specific cell lines</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Institute of Cancer Research UK</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Clonal Evolutionary dynamics of GBM</gtr:description><gtr:id>9B02F5E8-456A-4B90-AB50-FCC4B63815EE</gtr:id><gtr:impact>First confirmation of clonal evolution of solid human tumour
Paper in preparation</gtr:impact><gtr:outcomeId>KAy9NsEGy9H-1</gtr:outcomeId><gtr:partnerContribution>FISH analysis of copy number aberrations to general clonal evolutionary tree.</gtr:partnerContribution><gtr:piContribution>Derivation of cell lines from patients &amp;amp; use to generate orthotopic model of GBM. 
Sequential in vivo tumourigeneis
Generation of material for FISH analysis</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cancer Research UK Cambridge Institute</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Molecular Genetics of Glioblastoma</gtr:description><gtr:id>669B19CA-4BC9-4E73-A0D1-AFE623F966F9</gtr:id><gtr:impact>Identification of sampling bias in generating molecular genetic data from surgical specimens
2 papers under review</gtr:impact><gtr:outcomeId>Hrj67v8spwH-1</gtr:outcomeId><gtr:partnerContribution>Bioinformatic analysis of molecular genetics of GBM</gtr:partnerContribution><gtr:piContribution>Technique of Fluorescence-Guided Multiple Sampling (FGMS) developed to allow objective spatially discrete tumour sampling for molecular genetic analysis</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Patient support group activity</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>246E984C-D70E-464B-B8AF-854C77E99698</gtr:id><gtr:impact>Successful application for clinical trial funding to CRUK

Enhanced Brain CSG clinical trial portfolio 
Identification of barriers to recruitment to clinical trials</gtr:impact><gtr:outcomeId>UTQgY7KLM7z</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>APPG</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>11AC9EE4-9D2E-46F6-81B8-D24E71AFBC5B</gtr:id><gtr:impact>Prof Sir Mike Richards (National Clinical Director for Cancer) spoke to MPs and patient support groups at the Houses of Parliament highlighting some of the issues raised.

CRUK are planning to highlight brain cancer as a priority in their next strategic five year plan (2014-19).</gtr:impact><gtr:outcomeId>m22FrMiiS8Q</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>38000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>GALA-5</gtr:description><gtr:end>2013-06-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>DBACEE08-9A4F-4E9A-BE5A-6168BB9D3133</gtr:id><gtr:outcomeId>tjoqmAiMNcu</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>176900</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project grant</gtr:description><gtr:end>2016-06-02</gtr:end><gtr:fundingOrg>The Brain Tumour Charity</gtr:fundingOrg><gtr:fundingRef>10/136</gtr:fundingRef><gtr:id>D1AADA84-8FE3-412F-BE79-B57DB5B012D6</gtr:id><gtr:outcomeId>HEhwun5GRTU</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>189908</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BIDD Programme</gtr:description><gtr:end>2016-12-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:fundingRef>C9221/A16700</gtr:fundingRef><gtr:id>717FF7AB-18D6-4421-A82E-A0744C48355C</gtr:id><gtr:outcomeId>bSTqtoEZdf5</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Changing clinical practice</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>6B50044F-B25E-4421-90A2-E64CD9B50B4E</gtr:id><gtr:impact>Changes in process of care leading to reduced length of stay, enhanced patient care (shift from in-patient emergency-based practice to elective outpatient-based practice) and enhanced clinical trial recruitment (see Guilfoyle et al 2011)</gtr:impact><gtr:outcomeId>kZ4PQKpLnaQ</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>FGMS is a surgical technique designed to study spatial genomic heterogeneity in Glioblastoma</gtr:description><gtr:id>64BA2591-83B0-4476-A927-FFD881A044D8</gtr:id><gtr:impact>Increased recognition of the importance of understanding spatial genomic heterogeneity and its role in the emergence of resistant disease</gtr:impact><gtr:outcomeId>Mvk5ZdugapG</gtr:outcomeId><gtr:stage>Small-scale adoption</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Fluorescence-guided multiple sampling (FGMS)</gtr:title><gtr:type>Support Tool - For Fundamental Research</gtr:type><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Development of highly efficient derivation protocol for glioma stem-like cells based on adapting protocols for adult neural stem cell derivation.</gtr:description><gtr:id>6EED2574-B350-4F98-AC58-0BC08B10FD06</gtr:id><gtr:impact>Industrial collaboration with Genzyme to identify cell surface epitopes suitable for diagnostic or therapeutic targeting.</gtr:impact><gtr:outcomeId>r8r418obyjL</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Glioma Stem Cell Derivation Protocol</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>1626F227-0DD7-4D72-91CB-AF180BAC5A42</gtr:id><gtr:title>An efficient method for derivation and propagation of glioblastoma cell lines that conserves the molecular profile of their original tumours.</gtr:title><gtr:parentPublicationTitle>Journal of neuroscience methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8ece31ee30f39d3ff89a2feb06482632"><gtr:id>8ece31ee30f39d3ff89a2feb06482632</gtr:id><gtr:otherNames>Fael Al-Mayhani TM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0165-0270</gtr:issn><gtr:outcomeId>7F358BCC560</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2591F16C-22EB-4F6B-B292-6356F4A60E36</gtr:id><gtr:title>Glioblastoma cell lines derived under serum-free conditions can be used as an in vitro model system to evaluate therapeutic response.</gtr:title><gtr:parentPublicationTitle>Cancer letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/87901928088f43e2b8d8f456b2acf469"><gtr:id>87901928088f43e2b8d8f456b2acf469</gtr:id><gtr:otherNames>Kenney-Herbert EM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0304-3835</gtr:issn><gtr:outcomeId>pm_16479_29_21402437</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2E4960B9-119C-43A2-A10B-25B76440DC96</gtr:id><gtr:title>Widespread resetting of DNA methylation in glioblastoma-initiating cells suppresses malignant cellular behavior in a lineage-dependent manner.</gtr:title><gtr:parentPublicationTitle>Genes &amp; development</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2e764902cd8123a2a039be6621814302"><gtr:id>2e764902cd8123a2a039be6621814302</gtr:id><gtr:otherNames>Stricker SH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0890-9369</gtr:issn><gtr:outcomeId>pm_16479_29_23512659</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BFB307C1-CEA0-4C27-81DC-25AD00E8ED0D</gtr:id><gtr:title>Fluorescence-guided surgical sampling of glioblastoma identifies phenotypically distinct tumour-initiating cell populations in the tumour mass and margin.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/405661fdcf6221fcaf0188903b88709e"><gtr:id>405661fdcf6221fcaf0188903b88709e</gtr:id><gtr:otherNames>Piccirillo SG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>pm_16479_29_22722315</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>23B3F116-2154-478B-B0D5-EBC9418A8D1E</gtr:id><gtr:title>Enhanced stability and activity of temozolomide in primary glioblastoma multiforme cells with cucurbit[n]uril.</gtr:title><gtr:parentPublicationTitle>Chemical communications (Cambridge, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b3657164f4ced0285e0e26900694bfd7"><gtr:id>b3657164f4ced0285e0e26900694bfd7</gtr:id><gtr:otherNames>Appel EA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1359-7345</gtr:issn><gtr:outcomeId>pm_16479_29_22936104</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>034B7646-F424-40D8-B5E2-C4FF06202E86</gtr:id><gtr:title>Deep brain stimulation: eye movements reveal anomalous effects of electrode placement and stimulation.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cbd67da2978b906fa9ec8f116cdd42c4"><gtr:id>cbd67da2978b906fa9ec8f116cdd42c4</gtr:id><gtr:otherNames>Antoniades CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_16479_29_22427894</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>078A3CC6-952B-412B-93A1-41713F7C37FA</gtr:id><gtr:title>NG2 expression in glioblastoma identifies an actively proliferating population with an aggressive molecular signature.</gtr:title><gtr:parentPublicationTitle>Neuro-oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/06963756690210fad35035d987682c41"><gtr:id>06963756690210fad35035d987682c41</gtr:id><gtr:otherNames>Al-Mayhani MT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1522-8517</gtr:issn><gtr:outcomeId>pm_16479_29_21798846</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>21E41655-6BD3-4363-ADDE-82C791667961</gtr:id><gtr:title>Serum albumin and survival in glioblastoma multiforme.</gtr:title><gtr:parentPublicationTitle>Journal of neuro-oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/869ddaa55c73f5fff2caa5d1b8e89dc4"><gtr:id>869ddaa55c73f5fff2caa5d1b8e89dc4</gtr:id><gtr:otherNames>Borg N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0167-594X</gtr:issn><gtr:outcomeId>pm_16479_29_21409514</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>072C69AB-63BD-417E-8744-3BDC2CC9C831</gtr:id><gtr:title>Implementation of neuro-oncology service reconfiguration in accordance with NICE guidance provides enhanced clinical care for patients with glioblastoma multiforme.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/de49ceeeba6bbdb0d7189a130938fe75"><gtr:id>de49ceeeba6bbdb0d7189a130938fe75</gtr:id><gtr:otherNames>Guilfoyle MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>pm_16479_29_21610702</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8E6590FF-16F4-41CF-AF38-96129F5C2715</gtr:id><gtr:title>Genetic and functional diversity of propagating cells in glioblastoma.</gtr:title><gtr:parentPublicationTitle>Stem cell reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/405661fdcf6221fcaf0188903b88709e"><gtr:id>405661fdcf6221fcaf0188903b88709e</gtr:id><gtr:otherNames>Piccirillo SG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2213-6711</gtr:issn><gtr:outcomeId>56531c5a05d1e8.35783396</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B41E91C2-7B5B-4710-A88C-37E604A4E747</gtr:id><gtr:title>Anatomical perspectives on adult neural stem cells.</gtr:title><gtr:parentPublicationTitle>Journal of anatomy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/feadb7f46f684e47acb9298d8753bf83"><gtr:id>feadb7f46f684e47acb9298d8753bf83</gtr:id><gtr:otherNames>Watts C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0021-8782</gtr:issn><gtr:outcomeId>pm_16479_19_16185244</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D1E56D99-A247-40BE-80B5-D79D1DBC677B</gtr:id><gtr:title>Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial</gtr:title><gtr:parentPublicationTitle>The Lancet</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fb06d1571103e4e0bbb2fe7da6e4891f"><gtr:id>fb06d1571103e4e0bbb2fe7da6e4891f</gtr:id><gtr:otherNames>Palfi S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>54621b07404451.41532303</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0059BFDF-0887-4D85-92E2-8E7AF4E3CC2A</gtr:id><gtr:title>Establishing the efficacy of Gliadel wafers: progress towards a Phase III trial.</gtr:title><gtr:parentPublicationTitle>Acta neurochirurgica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/feadb7f46f684e47acb9298d8753bf83"><gtr:id>feadb7f46f684e47acb9298d8753bf83</gtr:id><gtr:otherNames>Watts C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0001-6268</gtr:issn><gtr:outcomeId>pm_16479_29_23108559</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>91A41BB9-F679-455E-BDD9-C60504749B8E</gtr:id><gtr:title>Environmental signals regulate lineage choice and temporal maturation of neural stem cells from human embryonic stem cells.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9fb120c58a3a06207c156f6b551ad790"><gtr:id>9fb120c58a3a06207c156f6b551ad790</gtr:id><gtr:otherNames>Joannides AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>pm_16479_19_17472984</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>68A167BA-F1D8-4A36-AF70-BA37C65F8DA5</gtr:id><gtr:title>A review of the role of stem cells in the development and treatment of glioma.</gtr:title><gtr:parentPublicationTitle>Acta neurochirurgica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/23f7279a0990fd4af942e54a29f63a96"><gtr:id>23f7279a0990fd4af942e54a29f63a96</gtr:id><gtr:otherNames>Heywood RM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0001-6268</gtr:issn><gtr:outcomeId>pm_16479_29_22527576</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D1A1CD76-5130-4BFB-B5A2-35FF8A47F4B3</gtr:id><gtr:title>High grade glioma--the arrival of the molecular diagnostic era for patients over the age of 65 years in the UK.</gtr:title><gtr:parentPublicationTitle>Clinical oncology (Royal College of Radiologists (Great Britain))</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/98a1a32ed202f060c091c68c07837b46"><gtr:id>98a1a32ed202f060c091c68c07837b46</gtr:id><gtr:otherNames>Jefferies SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0936-6555</gtr:issn><gtr:outcomeId>pm_16479_29_23615180</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A6241439-3428-4986-835E-6E5033B2E2B9</gtr:id><gtr:title>Astrocytes and oligodendrocytes can be generated from NG2+ progenitors after acute brain injury: intracellular localization of oligodendrocyte transcription factor 2 is associated with their fate choice.</gtr:title><gtr:parentPublicationTitle>The European journal of neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8733ceaf3ddea33d493f9edc0589f7e3"><gtr:id>8733ceaf3ddea33d493f9edc0589f7e3</gtr:id><gtr:otherNames>Zhao JW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0953-816X</gtr:issn><gtr:outcomeId>pm_16479_19_19473238</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G108/507</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>6393C0B5-F394-4AB6-9626-AD6D94C7BCB5</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Injuries and Accidents</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>